Posted in0 - No Apple Publish, 0Recent Headlines, 0Trending, 1gridNATION, 1gridNATIONandSTATE, Nation, Nation & World, Uncategorized, World, z-ntl-galley

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

The FDA said it awarded priority review vouchers to two companies studying psilocybin — the active ingredient in magic mushrooms — for hard-to-treat forms of depression. A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the vouchers.

Gift this article